Neuropace (NASDAQ:NPCE) specializes in creating advanced neuromodulation devices aimed at improving the quality of life for patients suffering from neurological disorders, particularly epilepsy. Focused on the development and commercialization of its flagship Responsive Neurostimulation (RNS) System, the company's primary objective is to provide innovative, data-driven solutions for epilepsy management. This system is designed to monitor brain activity and deliver personalized, responsive stimulation to prevent seizures before they happen. With a commitment to advancing neurological care through technology, Neuropace is dedicated to ongoing research and development efforts to expand its product offerings and improve patient outcomes.